TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02900326

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Telomerase activity on a blood sample

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Telomerase activity on a blood sample

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of life (questionnaires)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life (questionnaires)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cerebral IRMf

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral IRMf
Study: NCT02560818

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collection of a blood sample and breast and ovarian tissue
Description: a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: use of a previous blood collection for patients
Study: NCT03073499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oncological Home Hospitalization
Study: NCT04565691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment that is accepted to cause bacteremia in about 40% of the cases.
Study: NCT01586780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Test drink providing 9g protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Test drink providing 9g protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Test drink providing 9g protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Test drink providing 9g protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Test drink providing 9g protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Test drink providing 9g protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reference meal
Description: Control meal
Study: NCT04491357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: Intravenous calcium gluconate within 4 hours of skin closure after total thyroidectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline within 4 hours of skin closure after total thyroidectomy
Study: NCT00549016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTPE Encapsulation of Nitinol Stents
Description: Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
Study: NCT02519842

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04008693

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged Garlic Extract
Description: 2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 800 mg of maltodextrin (four capsules)
Study: NCT02519842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonist
Study: NCT03828175

Intervention type: PROCEDURE
Group type: OTHER
Intervention: spinal anesthesia monitoring
Description: After attaching all standard monitors (ECG, NIBP, pulse oximeter) and the COP bio-impedance monitor recording basal data (COP, CI, SV, CPI, Do2, DO2I, SVR, SVV.~During sitting position intrathecal anesthesia was conducted in the sitting position under complete aseptic condition using heavy bupivacaine 15mg (3ml) plus 10 mic dexamedatomedine 25G needle after 2 ml Lidocaine skin infiltration. lithotomy position till anesthesia level documented T4 and fixed and lower urinary tract endoscopy then shifting the patient to prone position and after adjustment of the prone position precautions 2 bellows one under the chest and one under the pelvis with pliable free moving abdomen jell ring under the patient head knees and in front of heels, then the basal data recording and after that data recording every 10 minutes till end of the operative procedure. Blood sampling at basal, postoperative
Study: NCT04396301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).
Description: Fydrane®. The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide type local anaesthetics) for each 0.2 ml dose, equivalent to 0.2 mg of tropicamide, 3.1 mg of phenylephrine hydrochloride and 10 mg of lidocaine hydrochloride for 1 ml.
Study: NCT01352546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: 150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
Study: NCT01572519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1, Cohort 1
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1, Cohort 2
Description: Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1, Cohort 3
Description: Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
Study: NCT03448328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTRALYS pea protein supplement
Description: 0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple juice
Description: 1.2 calories per kilogram body weight before and after eccentric exercise, and each of 4 mornings of recovery
Study: NCT01572519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1, Cohort 4
Description: Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2
Description: JNJ-40346527 at the recommended dose determined in Phase 1
Study: NCT03906643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-201
Description: HS-201 will be administered intravenously as a single dose
Study: NCT05927090

Intervention type: PROCEDURE
Intervention: Conservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair
Description: Cardiac arrest will be performed by administering a potassium-rich antegrade cardioplegia solution delivered directly into the coronary ostium or in the case of aortic regurgitation after insertion of the coronary sinus cannula.The aorta will be resected up to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion can be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget above every commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients demonstrating normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferable.

Intervention type: PROCEDURE
Intervention: Extensive Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)
Description: Patients who experienced dilatation of the sinuses of Valsalva \> 4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will receive replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure associated to AAR

Intervention type: PROCEDURE
Intervention: Extensive Ascending Aorta Replacement (AAR) with Total Arch Replacement (TARP)
Description: Total arch replacement procedures (TARP) will performed with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)

Intervention type: PROCEDURE
Intervention: Extensive Root and Ascending Aorta Replacement with Total Arch Replacement
Description: This extensive procedure will include complete replacement of the anterior thoracic aorta extending to part or all of the aortic arch. It will be performed with the previously reported techniques
Study: NCT04147273

Intervention type: DEVICE
Group type: OTHER
Intervention: Determination of postprandial glucose response by continuous glucose measurement after consuming different carbohydrate containing foods
Description: One day prior to the study beginning, participants were equipped with a CGM system (FreeStyle Libre®, Abbott Diabetes Care, Alameda, CA, USA). This CGM system provides glucose recordings every 15 min over a period of 14 days. The glucose data were downloaded manually by a scan with a handheld device.~On the second day of the study, participants consumed portions of these three test products containing 50 g of available carbohydrate on 3 separate days without a washout period. The products were tested in random order at the same time of the morning after a 10 h overnight fast. Venous blood samples were collected at 0, 15, 30, 45, 60, 75, 90, 105 and 120 min postprandial by inserting an intravenous cannula into a forearm vein. Capillary blood samples were obtained through finger pricking. Blood glucose levels in these samples were measured with a high quality SMBG system (ContourXT/Contour next, Ascensia Diabetes Care, Leverkusen, Deutschland, Germany).
Study: NCT03412929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honey Impregnated Dressing
Description: The investigational product being examined contains 100% Manuka honey and is ideal for difficult to dress wounds. The dressing provides a moist wound environment to help promote autolytic debridement. The dressing is ideal for partial or full thickness wounds with moderate-to-heavy drainage.
Study: NCT02055846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Realisation of blood sample, urinary sample and tumor biopsy
Study: NCT05480007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin and metformin
Description: sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin treatment (100mg per day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin group who received metformin (500mg three times per day)
Study: NCT04028687

Intervention type: DEVICE
Intervention: Taperloc Complete Stem
Description: Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
Study: NCT02325154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Oximeter
Description: Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
Study: NCT04130854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days
Description: 1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~2. Short course radiation therapy 5 Gy x 5 days~3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~4. Leucovorin 400mg/m2 IV Day 1 of each cycle~5. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX and Radiation Therapy 5Gy x 5 days
Description: 1. Short course radiation therapy 5 Gy x 5 days~2. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~3. Leucovorin 400mg/m2 IV Day 1 of each cycle~4. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle
Study: NCT00645658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testim, 1% testosterone gel
Description: Subjects apply contents of gel packet (Testim, 1% testosterone gel) to skin daily.
Study: NCT03106779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: 40 mg tablets was taken orally twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib
Description: 500 mg tablets was taken orally once daily (QD)
Study: NCT00969124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope
Description: Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
Study: NCT02067767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine/Dolutegravir
Description: At Day 1 (D1):~* group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~* group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1.
Study: NCT01118338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Redesigned Purevision Contact Lens
Description: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision Contact Lens
Description: Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
Study: NCT01125761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone 0.5 mg and 1.0 mg clemastine cream
Description: The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0,5 mg cream
Description: The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
Study: NCT02947048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L1-79
Study: NCT01343342

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Description: 3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
Study: NCT02709174

Intervention type: PROCEDURE
Intervention: blood draw
Description: blood draw
Study: NCT04652076

Intervention type: DRUG
Group type: OTHER
Intervention: NP137
Description: Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.

Intervention type: DRUG
Group type: OTHER
Intervention: NP137
Description: Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
Study: NCT06617117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity combined exercise
Description: The main part consisted of interval cycling exercise, comprising 5x2 min at the second ventilatory threshold interspersed with 4x2 min at the first ventilatory threshold, followed by 2-min unloading pedalling. Subsequently, participants completed resistance exercises (2 sets of 12 repetitions), targeting the same muscle groups of the moderate-intensity exercise, at an intensity of 80% of their 1 repetition maximum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity combined exercise
Description: The main part of the exercise session consisted of an 18-min cycling continuous aerobic exercise at the first ventilatory threshold, followed by 2-min of unloading cycling. Subsequently, participants engaged in resistance exercises - 2 sets of 12 repetitions at 60% of their one repetition maximum. These resistance exercises were part of a machine-assisted circuit training program, encompassing Chest Press, Leg Curl, Low Row, Leg Press, Lat Pull-down, and Leg Extension.
Study: NCT04567758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises
Study: NCT03026309

Intervention type: OTHER
Intervention: no intervantion
Description: no intervention is being performed, only observational evaluations.

Intervention type: OTHER
Intervention: no intervantion
Description: no intervention is being performed, only observational evaluations.
Study: NCT02104817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova® (omega-3 carboxylic acids)
Description: Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corn oil control
Description: corn oil control arm
Study: NCT01917435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-stylet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope
Study: NCT04652076

Intervention type: DRUG
Group type: OTHER
Intervention: NP137
Description: Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
Study: NCT00972907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine coated suppositories
Description: 12 mg Nifedipine coated suppositories BID
Study: NCT02316756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo which will be given as oral suspension
Study: NCT00642421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2L-OCT-01 PR, 10 or 20 mg
Description: The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2L-OCT-01 PR, 20 mg
Description: The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
Study: NCT03291041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study: NCT02947048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L1-79

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L1-79

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L1-79

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02838381

Intervention type: OTHER
Group type: OTHER
Intervention: Additional biological samples
Description: blood and tissue samples
Study: NCT00304161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: 40 to 80 mg orally once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 to 80 mg orally once daily for 8 weeks
Study: NCT02566941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)
Study: NCT01725152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: oral suspension, given in 3 divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: oral suspension, given in 3 divided doses
Study: NCT04652076

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.